Problems with Generics (May)

Date of Issue: 05/01/2021 | Volume: 19 | Number: 5

Issue Links:Learning Objectives | Editorial Information

Generic medications are supposed to work as well as the brands, so why have so many been recalled in recent years? Katherine Eban explains the problem. Also, vitamin D in psychiatric disorders, topiramate in PTSD, and the real risk that bipolar patients face when they stop their mood stabilizer.

In This Issue

In Brief

In Brief: Lamotrigine Gets a New Warning

Topics: Antipsychotics | Carbamazepine | Lamotrigine

A new warning now sits beneath the list of life-threatening allergic reactions that can happen with lamotrigine. The anticonvulsant is suspected of causing cardiac arrhythmias in susceptible patients by slowing ventricular conduction and widening the QRS.

Read More
Clinical Update

A Review of Medications for PTSD, With a Focus on Topiramate

Topics: PTSD

Topiramate is not first-line in PTSD, but it does have a role, particularly when alcohol use is part of the picture.

Read More
Expert Q&A

What’s Wrong With Generics?

Topics: Generics | Pharmaceutical Industry

Generic recalls are on the rise: Bupropion, methylphenidate, and metformin, to name a few. Katherine Eban explains the limits of FDA oversight, and what we can do to protect our patients when quality control cones under suspicion.

Read More
Clinical Update

Depression, Vitamin D, and COVID-19

Topics: COVID19 | Medical Comorbidities | Vitamin D

Vitamin D deficiency is causing everything from depression to cancer to COVID-19, at least that’s what our patients are hearing. Paul Riordan looks at the strength of that research and clarifies when to check levels and when to supplement.

Read More
Research Update

Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?

Topics: Bipolar Depression | Bipolar Disorder | Bipolar II | Lithium | Medication adherence | Mood Stabilizers | retention

Textbooks tell us that patients with bipolar I disorder need to take mood stabilizers for life. But what are the real risks of stopping these medications? A new meta-analysis provides some clarity.

Read More
CME Post-Test

CME Post-Test - Problems with Generics, TCPR, May 2021

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.

Read More